Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
stocks
Impact of ANZ’s huge fine
stocks
Acquisition a sign of weakness for overvalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,156.70 | 4.20 | 0.05% |
CAC 40 | 7,896.93 | 71.69 | 0.92% |
DAX 40 | 23,748.86 | 50.71 | 0.21% |
Dow JONES (US) | 45,883.45 | 49.23 | 0.11% |
FTSE 100 | 9,277.03 | 6.26 | -0.07% |
HKSE | 26,466.45 | 19.89 | 0.08% |
NASDAQ | 22,348.75 | 207.64 | 0.94% |
Nikkei 225 | 44,911.81 | 143.69 | 0.32% |
NZX 50 Index | 13,254.08 | 45.77 | 0.35% |
S&P 500 | 6,615.28 | 30.99 | 0.47% |
S&P/ASX 200 | 8,883.60 | 2.90 | 0.03% |
SSE Composite Index | 3,856.45 | 4.05 | -0.10% |